Paradigmenwechsel in der Diabetologie

Diabetes ist weltweit auf dem Vormarsch. Neben dem Typ-1-Diabetes, bei dem durch die chronische Erkrankung kein Insulin mehr gebildet werden kann, existiert die Typ-2-Variante. Auch beim Typ-2-Diabetes ist die Veranlagung zur Krankheit vorhanden. Jedoch lässt sich in diesem Falle das Risiko, an Diabetes zu erkranken, durch den eigenen Lebensstil verringern. Ein neuer patientenorientierter Ansatz soll nun das Leben mit Diabetes erleichtern.

• Literatur

• 1 American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45: S1-S2 DOI: 10.2337/dc22-Sint.
• 2 Boughton CK. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nature Med 2021; 27: 1471-1476
• 3 Buse JB. et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493
• 4 Clodi M. et al. Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019). Wien Klin Wochenschr 2019; 131: 27-38
• 5 Davies MJ. et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol 2022; 21: 144
• 6 Davies MJ. et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65: 1925-1966
• 7 FDA, US Food and Drug Administration. Im Internet: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes abgerufen am 25.7.2023
• 8 Gaede P. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
• 9 Ha J. et al. Pioglitazone use and reduced risk of dementia in patients with diabetes mellitus with a history of ischemic stroke. Neurology 2023; 100: 1799-1811
• 10 Herold KC. et al. Type 1 Diabetes TrialNet Study, an anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381: 603-613
• 11 Konstantinou P. et al. Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med 2020; 10: 1390-1398
• 12 Marso SP. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
• 13 Palanca A. et al. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther 2023; 14: 723-736
• 14 Sims EK. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13: eabc8980
• 15 Stiefelhagen P. Paradigmenwechsel in der Diabetestherapie? . MMW – Fortschritte der Medizin 2020; 162: 71
• 16 Zinman B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128